Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

被引：157

作者：

Alici, Evren ^{[1
,2
]}

Sutlu, Tolga ^{[1
]}

Boejrkstrand, Bo ^{[1
]}

Gilljam, Mari ^{[1
]}

Stellan, Birgitta ^{[1
]}

Nahi, Hareth ^{[1
]}

Quezada, Hernan Concha ^{[1
,2
]}

Gahrton, Goesta ^{[1
]}

Ljunggren, Hans-Gustaf ^{[2
]}

Dilber, M. Sirac ^{[1
]}

机构：

[1] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Dept Med, SE-14186 Stockholm, Sweden

[2] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden

来源：

BLOOD | 2008年 / 111卷 / 06期

关键词：

D O I：

10.1182/blood-2007-09-110312

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple myeloma (MM) is an incurable plasma cell malignancy with poor outcome. The most promising therapeutic options currently available are combinations of transplantation, targeted pharmacotherapy, and immunotherapy. Cell-based immunotherapy after hematopoietic stem-cell transplantation has been attempted, but with limited efficacy. Natural killer (NK) cells are interesting candidates for new means of immunotherapy; however, their potential clinical use in MM has not been extensively studied. Here, we explored the possibility of expanding NK cells from the peripheral blood of 7 newly diagnosed, untreated MM patients, using good manufacturing practice (GMP)compliant components. After 20 days of culture, the number of NK cells from these patients had expanded on average 1600-fold. Moreover, expanded NK cells showed significant cytotoxicity against primary autologous MM cells, yet retained their tolerance against nonmalignant cells. Based on these findings, we propose that autologous NK cells expanded ex vivo deserve further attention as a possible new treatment modality for MM.

引用

页码：3155 / 3162

页数：8

共 46 条

[31] Prospects for the use of NK cells in immunotherapy of human cancer [J].